News blog

NIH launches elite programme for clinical researchers

The decline of a once-common species – the physician-scientist – has for decades been a subject of concern for those charged with steering the biomedical research enterprise. Now, the National Institutes of Health (NIH) is announcing a new programme that will handsomely finance a small, select cadre of young investigators, in hopes of seeding a languishing pipeline of clinical researchers.

The agency’s Lasker Clinical Research Scholars programme opened its doors on 2 February with this request for applications that are due on April 4. The programme will launch young health professionals as clinical researchers in two stages. First it will bring them to NIH’s Bethesda campus for five to seven years, during which they will conduct clinical research at the agency’s huge research hospital, the Clinical Center. The scholars will join the tenure-track ranks as independent principal investigators at one of NIH’s 27 institutes and centres – which one will depend on the nature of their project. In addition to salary, they will be provided with everything from research space and nurses to lab support, at a cost per scholar that the agency estimates will be $1 million per year. Applicants need to be young-ish: within six years of completing the final piece of their medical training, and with a license to practice in the United States. In addition to physicians, nurse-PhDs, osteopaths and dentists are welcome to apply. So are non-US citizens. The agency plans to hire at least three scholars in this, the programme’s first year. It will ultimately support 30 to 40 participants on the NIH campus.

In a second stage of the award, scholars who pass muster would have the option of staying on at the agency as tenured intramural investigators, or would be eligible to apply for an extramural research grant that would fund a project at an academic medical centre where they would continue as clinical researchers. The research grant would provide up to $500,000 per year of NIH support for up to five years, as well as indirect costs paid by NIH to the institution where they land.

That’s crucial at a time when, at financially strained academic medical centres, there is increasing pressure on young doctors to generate institutional income by seeing patients, rather than engaging in costly and time-consuming clinical research, says Michael Gottesman, NIH’s deputy director for intramural research.

“There is a burgeoning interest in translating more of our basic science into clinical applications,” he says. “What’s going to limit us is talented people who know how to do clinical research. Hopefully this will help fill that gap.”

Gottesman notes that the length and two-stage nature of the award is unusual: “I can’t think of any other example where we’ve had a single mechanism allowing people to start a career at NIH and continue it outside NIH.”

The programme will be financed from existing intramural and, eventually, extramural, budgets at individual NIH institutes. It will have no formal affiliation with the proposed National Center for Advancing Translational Sciences (NCATS), which has been a font of controversy of late. The foundation established by Albert and Mark Lasker, in honour of whom the award is named, will contribute connections to mentors for awardees, but no funds.


  1. Report this comment

    Matt Gordon said:

    This is an excellent initiative. Bound to have enormous and significant impact in the way leader citizens are trained.

    A counterpart initiative for basic scientists would be great !!

  2. Report this comment

    Allan Delonie said:

    The Hippocratic Oath is an oath historically taken by doctors swearing to practice medicine ethically. Much, and never too much, is known about how academic medical centers deal with their responsibilities to train physicians, physician scientists and the diverse biomedical force much needed and expected for a New World Health and Economic Order. Ethical compass is part of The Dream. Yet, a forthcoming reality is taking shape on the wings of an enthusiastically committed cadre of evidence-based leaders with strong scientific foundations, driven by humanistic values and altruistic goals.

    Indeed, the contribution to a New World Health and Economic Order is a major objective at one of the world’s finest institutions, the University of Pennsylvania. To this end, and as reported by the Daily Pennsylvanian on September 16, 2010

    “School of Medicine initiatives to place more women into top academic positions triumphed this fall with the addition of Ophthalmology chairwoman. And with five more department chair spots on the market, Penn Med’s commitment to enhancing faculty diversity is coming into play.

    “It’s one of our number one missions to have a diverse faculty,” Penn Med Executive Director of Faculty Affairs Victoria Mulhern said. “It’s something we’re involved with every day.”

    Penn Med Dean Arthur Rubenstein is the driving force behind many of the initiatives to diversify the faculty, particularly by placing more women into top positions. Of Rubenstein’s six vice chairs, two are female. Four of the Penn Med Executive Directors are women, and four more hold vice president and senior vice president positions.

    But why is it so important to get women into higher academic positions, or to diversify faculty members at all? Rubenstein cited the importance of providing all students with faculty members with whom they can identify and placed emphasis on the educational value of a diverse staff.

    “There’s a great commitment in Penn Med to diversify leadership in order to provide all students with role models they can identify with and to enhance the quality of their educational experience,” he said.

    For search committees, this initiative begins with the members themselves, who are chosen by the dean and the committee chairperson, and selected “so they will have a sensitivity to all individuals,” Rubenstein said.

    Search committees are now in the process of finding new chairpersons for the Neurology, Neuroscience, Pathology and Laboratory Medicine, Dermatology and Genetics Departments, and are considering “candidates that are broadly representative,” Bellini said.” This is The Daily Pennsylvanian reporting.

    No question that, if implemented as Rubenstein has consistently thought and planned, there will be an extraordinarily diverse, reinvigorated School of Medicine Faculty generating the seeds and fruits for the best New World Health and Economic Order. It is a matter of Hippocratic Oath.

    But for the sake of diversity itself and diverse opportunities, NIH please don’t place Rubenstein in the Review Committees for these Awards.

Comments are closed.